- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04539600
Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer
August 14, 2021 updated by: Zhen-Wei Peng, Sun Yat-sen University
Induction Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Cancer
The study is a single center phase II trial.
The purpose is to investigate both the efficacy and safety of chemotherapy combined with anti-PD-1 antibody Followed by chemoradiotherapy in locoregionally advanced hypopharyngeal cancer.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
23
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital of Sun Yat-sen University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18-75 years;
- Hypopharyngeal squamous cell carcinoma confirmed by histopathology;
- No distant metastases, stage III-IV (According to the 8th UICC/AJCC TNM staging system );
- At least 1 measurable lesion (according to RECIST1.1), and the lesion has not been treated;
- Provide tissues for biomarker analysis;
- ECOG PS 0-1;
- Adequate hematologic, hepatic and renal function: ANC ≥ 1.5x10^9/L, Hb ≥ 90g/L, PLT ≥ 100 x10^9/L, albumin ≥ 28g/L, total bilirubin < 1.5×ULN at diagnosis or after biliary drainage, ALT and AST < 5×ULN, BUN、CREA<1.5×ULN, creatinine clearance rate ≥ 45ml/min;
- Contraception during the study;
- At least 12 weeks of life expectancy;
- Willing to join the study and sign informed consent.
Exclusion Criteria:
- Allergic to any component of carrelizumab, cisplatin and other platinum drugs;
- Have received anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or CTLA-4 antibody therapy in the past;
- Received biological treatment or participated in clinical trial of other drugs or devices within 4 weeks before enrollment;
- Have other malignant tumors within 5 years, except for fully treated basal cell/squamous cell skin cancer/cervical cancer;
- Have corticosteroids (>10 mg prednisone equivalent dose per day) or other immunosuppressive agents for systemic treatment within 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergies, nausea or vomiting;
- Uncontrolled clinical symptoms or diseases of the heart, such as: heart failure above NYHA II, unstable angina, myocardial infarction within 1 year;
- Have severe infections (CTCAE> Grade 2) occurred within 4 weeks before the first use of the study drug;
- Have active autoimmune diseases, autoimmune diseases, but not including autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone; type 1 diabetes with stable doses of insulin; vitiligo or cured childhood asthma/allergies;
- A history of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation;
- A history of interstitial lung disease (excluding radiation pneumonia that has not been treated with hormones) and a history of non-infectious pneumonia;
- Active tuberculosis, having antituberculosis therapy at present or within 1 year;
- Have active hepatitis B (HBV DNA ≥2000 IU/mL or 10~4 copies/mL) and hepatitis C;
- Have other uncontrollable comorbidities;
- Knowing a history of psychotropic drug abuse, alcohol or drug abuse;
- Pregnant or breastfeeding, or expect to become pregnant during the clinical trial period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: induction chemotherapy + anti-PD-1 antibody
Camrelizumab (200 mg, Q3w, 2 cycles in total) combined with induction chemotherapy (taxane-containing regimen, Q3w, 2 cycles in total) followed by concurrent radiotherapy and chemotherapy.
|
Camrelizumab is a type of anti-PD-1 antibody that could enhance the immune system of the patient to fight cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival, PFS
Time Frame: 1 year
|
Defined as the time from randomization until disease progression or death from any cause, whichever happens first.
Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and progression free.
Patients not having an event will be censored at the date last seen alive.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 1 year
|
Defined as the portion of patients with a tumor size reduction of a predefined amount for a minimum time period.
Tumor response will be measured according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1.
|
1 year
|
Duration of Response(DoR)
Time Frame: 1 year
|
Response duration is measured from the time of initial response until documented tumor progression.
|
1 year
|
Disease Control Rate (DCR)
Time Frame: 1 year
|
Refers to the proportion of patients whose tumors have shrunk or been stable for a certain period of time, including cases of complete response (CR), partial response (PR), or stable disease (SD).
|
1 year
|
Overall Survival (OS)
Time Frame: 1 year
|
Defined as the time from randomization until death from any cause.
Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive.
Patients remaining alive throughout the duration of the study will have their survival time censored on the date last seen alive.
|
1 year
|
Adverse events (AE)
Time Frame: 1 year
|
Adverse events during the treatment period using Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2020
Primary Completion (ANTICIPATED)
July 31, 2022
Study Completion (ANTICIPATED)
December 12, 2022
Study Registration Dates
First Submitted
September 1, 2020
First Submitted That Met QC Criteria
September 1, 2020
First Posted (ACTUAL)
September 7, 2020
Study Record Updates
Last Update Posted (ACTUAL)
August 19, 2021
Last Update Submitted That Met QC Criteria
August 14, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- hypopharyngeal SCC 002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypopharyngeal Cancer
-
Wake Forest University Health SciencesTerminatedHead and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditionsUnited States
-
University Hospital OstravaRecruitingLaryngeal Disease | Laryngeal Lesions | Hypopharyngeal Lesions | Suspected Laryngeal Cancer | Suspected Hypopharyngeal Cancer | Proven Laryngeal Cancer | Proven Hypopharyngeal CancerCzechia
-
Chinese PLA General HospitalRecruiting
-
Samsung Medical CenterCompletedHypopharyngeal CancerKorea, Republic of
-
The Second People's Hospital of SichuanBiotech Pharmaceutical Co., Ltd.UnknownHypopharyngeal Cancer | Oropharyngeal CancerChina
-
University of Alabama at BirminghamCompletedHead and Neck Cancer | Hypopharyngeal Cancer | Oropharyngeal Cancer | Upper Aerodigestive Tract NeoplasmsUnited States
-
Sun Yat-sen UniversityRecruitingHypopharyngeal CancerChina
-
Fudan UniversityShanghai Zhongshan Hospital; Ruijin Hospital; Shanghai Ninth People's Hospital... and other collaboratorsRecruitingHypopharyngeal Cancer | Larynx CancerChina
-
Fudan UniversityRecruitingLaryngeal Cancer | Hypopharyngeal CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Unknown
Clinical Trials on Camrelizumab
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
Peking UniversityNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruitingNasopharyngeal Carcinoma | Oligometastasis | RadiotherapyChina
-
Fudan UniversityRecruiting
-
Fujian Medical University Union HospitalRecruitingRadiotherapy | Immunotherapy | Esophageal NeoplasmChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Henan Provincial People's HospitalNot yet recruiting